Perspective Therapeutics CATX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -41.4%+1.9pp | -43.3%+28.3pp | -71.6%-59.1pp | -12.6%+2.1pp | |
| Return on assets | -33.9%+2.2pp | -36.1%+23.5pp | -59.6%-47.7pp | -12%+1.7pp | |
| Return on invested capital | -55%+5.2pp | -60.3%— | —— | —— | |
| Liquidity | |||||
| Current ratio | 5.2×-7.5× | 12.7×+11.6× | 1.1×-16.0× | 17.1×-17.4× | |
| Quick ratio | 5.2×-7.5× | 12.7×+11.6× | 1.1×-15.2× | 16.3×-17.8× | |
| Cash ratio | 1.1×-2.3× | 3.4×+2.8× | 0.6×-6.1× | 6.7×-26.0× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×— | —— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×— | —— | |
| Per Share | |||||
| Book value per share | $2.80-37.8% | $4.51+60.6% | $2.81— | —— | |
| Valuation | |||||
| Market capitalization | $342.14M+33.2% | $215.6M+91.2% | $112.78M+217% | $35.53M-35.8% | |
| Enterprise value | $292.34M+35.2% | $158.03M+49.0% | $106.05M— | —— | |
| Price / book | 1×+0.1× | 0.7×-0.8× | 1.5×+0.9× | 0.7×-0.2× | |
| Free cash flow yield | -31.4%+9.0pp | -33.7%0.0pp | -33.7%— | —— | |
| Earnings yield | -32.5%+0.7pp | -36.8%+4.5pp | -41.2%-20.1pp | -21.1%-10.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Perspective Therapeutics's profit margins?
- Perspective Therapeutics (CATX) runs a 33.1% gross margin and a -292.7% operating margin, with a -218.4% net margin.
- Where do Perspective Therapeutics's ratios come from?
- Every ratio is computed from Perspective Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
